4th Quarter - Report

MEHLMAN CONSULTING, INC. for VIZIENT INC

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

340b drug pricing program. Issues related to pharmacy benefit manager reform. Health care workforce. Health care supply chain. Health care drug shortages. Pandemic All-Hazard Preparedness Act Reauthorization. The Stop Drug Shortages Act (No Bill Number) discussion draft. H.R. 3008 - The Drug Shortage Prevention Act. H.R. 3810 - The Drug Origin Transparency Act.

LobbyistCovered position, as disclosed
LAUREN ARONSON —
ALYENE MLINAR New Pol Adv (Maj Leader Scalise); Pol Adv (Min Whip Scalise); Pol Adv (House Oversight/Govt Reform Comm); Prof Staff Member (Ways and Means Subcom on Health/Brady), Pol Adv (Sen Rep Policy Comm/Barrasso); Leg Asst (Senator Ben Sasse)
DEAN ROSEN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 3810 (118th), H.R. 3008 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.